NCT05564286 2024-02-06
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
Shantou University Medical College
Phase 3 Completed
Clinical Trials
11 trialsNCT05841849 2023-05-03
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Not yet recruiting
NCT05230654 2022-02-09
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
Shanghai Children's Medical Center
Phase NA Unknown
NCT04873284 2021-05-10
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
Shanghai Children's Medical Center
Phase NA Unknown
NCT01874119 2018-06-07
HDIL2/Emend
St. Louis University
Phase 2 Terminated
NCT01031953 2017-05-09
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT01432015 2017-03-28
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Gynecologic Oncology Associates
Phase 4 Completed
NCT01736917 2016-05-25
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Hoosier Cancer Research Network
Phase 2 Completed
NCT01490060 2016-04-11
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
M.D. Anderson Cancer Center
Phase NA Completed
NCT01074697 2015-04-24
GAND-emesis
Odense University Hospital
Phase 3 Completed
NCT02407600 2015-04-03
Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy
State University of New York - Upstate Medical University
Phase 2 Unknown